Cupric Chloride

Identification

Name
Cupric Chloride
Accession Number
DB09131
Type
Small Molecule
Groups
Approved, Investigational
Description

Cupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

Structure
Thumb
Synonyms
  • Copper chloride
  • Copper(2+) chloride
  • copper(II) chloride
  • Cupric chloride anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Cupric chloride dihydrateS2QG84156O10125-13-0MPTQRFCYZCXJFQ-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Cupric cationionicFV4Y0JO2CX15158-11-9JPVYNHNXODAKFH-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CopperInjection, solution0.4 mg/1mLIntravenousHospira, Inc.2005-02-28Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Trace Elements for Injection - Liq IVCupric Chloride (2.68 mg) + Chromic chloride (.102 mg) + Manganese chloride (1.44 mg) + Zinc chloride (10.42 mg)LiquidIntravenousFaulding Consumer, Inc.1998-06-152001-07-30Canada
Trace Elements Injection USPCupric Chloride (0.42 mg) + Chromic chloride (6 mcg) + Manganese chloride (0.37 mg) + Zinc chloride (1.67 mg)SolutionIntravenousPfizer1983-12-31Not applicableCanada
Trace Elements Solution InjCupric Chloride (2.68 mg) + Chromic chloride (.102 mg) + Manganese chloride (1.44 mg) + Zinc chloride (10.42 mg)SolutionIntravenousDavid Bull Laboratories (Pty) Ltd.1991-12-311998-08-13Canada
Categories
UNII
P484053J2Y
CAS number
7447-39-4
Weight
Average: 134.452
Monoisotopic: 132.867306493
Chemical Formula
Cl2Cu
InChI Key
ORTQZVOHEJQUHG-UHFFFAOYSA-L
InChI
InChI=1S/2ClH.Cu/h2*1H;/q;;+2/p-2
IUPAC Name
dichlorocopper
SMILES
Cl[Cu]Cl

Pharmacology

Indication

For use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).

Associated Therapies
Pharmacodynamics

Copper is an essential nutrient which serves as a co factor for serum ceruloplasmin, an oxidase necessary for proper formation of the iron carrier protein, transferrin. Copper also helps maintain normal rates of red and white blood cell formation. Providing copper during Total Parenteral Nutrition helps prevent development of the following deficiency symptoms: Leukopenia, neutropenia, anemia, depressed ceruloplasmin levels, impaired transferrin formation, secondary iron deficiency and osteoporosis.

Mechanism of action

The in vitro interaction of organic copper compounds with rat liver glutathione S-transferases was studied with reduced glutathione and 1-chloro-2,4-dinitrobenzene as substrates. Both organic and inorganic copper are spontaneously conjugated with glutathione, but interact with glutathione S-transferase by direct binding to these proteins.

TargetActionsOrganism
UVitamin K-dependent protein CNot AvailableHuman
UCystatin-BNot AvailableHuman
Absorption

Mean copper absorption of 57 percent (range 40 to 70 per cent) following oral administration of 0.4 - 4.5 mg copper (as copper acetate) to four volunteers. An early human study suggested a maximum blood copper concentration was reached some two hours after oral copper chloride administration (1.5 - 12 mg copper)

Volume of distribution

Copper is distributed to all tissues with the highest concentrations in liver, heart, brain, kidneys and muscle. Intracellular copper is predominantly metallothionein-bound.
Reported copper in the lungs, liver, kidney, blood, bile and stomach (33.7, 35.1, 41.4, 13.8, 2.8, and 2988 µg/g wet weight respectively)

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Renal

Half life
Not Available
Clearance
Not Available
Toxicity

LD50 not available Copper toxicity can produce prostration, behavior change, diarrhea, progressive marasmus, hypotonia, photophobia and peripheral edema. Such symptoms have been reported with a serum copper level of 286 mcg/dl. Copper toxicity can also result in hemolysis and liver toxicity, including hepatic necrosis which may be fatal. D-penicillamine has been reported effective as an antidote.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Pubchem [Link]
  2. inChem [Link]
External Links
PubChem Compound
24014
PubChem Substance
310265046
ChemSpider
22447
ChEBI
49553
ChEMBL
CHEMBL1200553
HET
CUL
PDB Entries
1d40

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentProstate Cancer1
1, 2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
1, 2SuspendedTreatmentGlioblastoma Multiforme (GBM)1
2Active Not RecruitingTreatmentRecurrent Glioblastoma1
2CompletedTreatmentNPDR - Non Proliferative Diabetic Retinopathy / Type 2 Diabetes Mellitus1
2Not Yet RecruitingTreatmentGlioblastoma Multiforme (GBM)1
4RecruitingBasic ScienceHormonal Contraception1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous0.4 mg/1mL
LiquidIntravenous
SolutionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.52ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity12.27 m3·mol-1ChemAxon
Polarizability7.27 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as transition metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Transition metal salts
Sub Class
Transition metal chlorides
Direct Parent
Transition metal chlorides
Alternative Parents
Inorganic chloride salts
Substituents
Transition metal chloride / Inorganic chloride salt / Inorganic salt
Molecular Framework
Not Available
External Descriptors
inorganic chloride, copper molecular entity (CHEBI:49553)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids (PubMed:25618265). Exerts ...
Gene Name
PROC
Uniprot ID
P04070
Uniprot Name
Vitamin K-dependent protein C
Molecular Weight
52070.82 Da
References
  1. Bar-Or D, Rael LT, Winkler JV, Yukl RL, Thomas GW, Shimonkevitz RP: Copper inhibits activated protein C: protective effect of human albumin and an analogue of its high-affinity copper-binding site, d-DAHK. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1388-92. [PubMed:11820775]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
This is an intracellular thiol proteinase inhibitor. Tightly binding reversible inhibitor of cathepsins L, H and B.
Specific Function
Cysteine-type endopeptidase inhibitor activity
Gene Name
CSTB
Uniprot ID
P04080
Uniprot Name
Cystatin-B
Molecular Weight
11139.555 Da
References
  1. Zerovnik E, Skerget K, Tusek-Znidaric M, Loeschner C, Brazier MW, Brown DR: High affinity copper binding by stefin B (cystatin B) and its role in the inhibition of amyloid fibrillation. FEBS J. 2006 Sep;273(18):4250-63. [PubMed:16939620]

Enzymes

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Oxidoreductase activity
Specific Function
Catalyzes the reversible oxidation of malate to oxaloacetate.
Gene Name
mdh
Uniprot ID
P61889
Uniprot Name
Malate dehydrogenase
Molecular Weight
32337.065 Da
References
  1. CHEMbl [Link]

Drug created on September 29, 2015 11:37 / Updated on November 02, 2018 08:58